Navigation Links
New and unique treatment for Psoriasis patients

Psoriasis patients who have been long-awaiting new options in treatment, now have fresh hope with the Food and Drug Administration's approval of the new drug, Amevive. This unique drug targets renegade immune cells to control hard-to-treat psoriasis. Psoriasis has been thought to occur when the immune system goes amok and cells called memory effector T cells prompt skin inflammation. The treatments that are currently available for psoriasis range from ointments to ultraviolet therapy to other injected drugs that can broadly suppress// the immune system. The new drug Amevive, however has been designed to target only the harmful T cells, instead of the entire immune system. Physicians have been eagerly awaiting the drug as it works differently from those drugs that are available in the market presently.

The drug, whose effect has not yet been compared with existing treatments, will be marketed in intravenous and intra-muscular injection forms. The treatment, for a 12-week course, will cost between $7000 and $10,000 and the weekly dose will be administered under the supervision of a doctor.

Biogen Inc., the makers of the drug, sponsored a study, which involved patients with chronic psoriasis that covered at least 10 percent of their bodies, and gave them either Amevive or dummy injections. They found that 40 per cent of patients on the Amevive drug saw their psoriasis symptoms cut in half, as compared to about 10 percent of placebo-treated patients. A small number of patients even saw their lesions almost vanish, for at least a while. Though the duration for which the effect lasted was not known, a small subset of patients went seven months or longer before needing additional treatment. The FDA's Dr. Karen Weiss cautioned that though the drug has a much more selective effect, it is still too soon to say it is very selective and very safe. In fact, she added that patients on the drug would require a blood test before each weekly dose to ensure the
'"/>




Page: 1 2

Related medicine news :

1. A unique factor in breathing disorder
2. Pink Shawl Project is a unique initiative
3. Thyroid hormone treatment hastens recovery after cardiac surgery
4. Feeding channel created by malaria parasite - a new target for malaria treatments
5. Now umbilical cord helps in stroke treatment.
6. Now AIDS treatment comes dirt-cheap
7. Breast cancer treatment to be determined by gene test
8. Hemopurifier may revolutionise AIDS treatment
9. New drug helps boost cancer treatment
10. Antidepressants come in handy for patients on treatment for hepatitis, cancers and multiple sclerosis
11. Experimental treatment for Ebola Virus Shows promising results in mice

Post Your Comments:
(Date:11/25/2009)...5/PRNewswire-USNewswire/--TheBlackAIDSInstituterec...iveleadershipfor2010. ,, ThenewBoardMembersarea...policy,law,finance,governmenthealthprograms,editor...romawiderangeofpersonalbackgroundsincludingbothhet...hemselves,andrepresentingmultipleagegroups. ,, ...
(Date:11/25/2009)...ndorsements,Business,andPressJoinEfforttoEducate ...-Onceagain,theNationalBipolarFoundationandtheMedic...Safe,tilStable"program,whichisnowbeingwidelyaccept....Today,theNationalBipolarFoundationreceivedaprocla...omtheLt.GovernorofLouisianaMitchLandrieu.TheNation...
(Date:11/25/2009)... evidence of a statistically significant survival ...se estrogen receptor (ER)-positive tumors had high...118 (ER-alpha S118-P), according to a brief commun...al of the National Cancer Institute . , Approxim...moxifen. Preclinical studies have shown that ER-al...
(Date:11/25/2009)...lood pressure? This simple question has been the ...ess-related gene Modulates High Blood Pressure in ... This simple question has been the focus of intens...or the first time established a link between a nov...e to stress in mice as well as humans. The studies...
(Date:11/25/2009)...to fight rheumatoid arthritis, could help newly di...SDAY, Nov. 25 (HealthDay News) -- A drug commonly ...d arthritis now also shows some promise in helping..., The drug, rituximab (Rituxan), helped patients ...ugh the disease had destroyed some of their pancre...
Breaking Medicine News(10 mins):Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:New stress-related gene modulates high blood pressure in mice and men 2Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3
.... 31 Biopure Corporation,(Nasdaq: BPUR ) announc...ommon stock will revert from BPURD to BPUR at the ... Outstanding warrants that trade on the OTCBB,will...re Corporation develops, manufactures and markets ...
.../PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(TS...company focused on,endocrine therapy and oncology,...d operating results before market open on Wednesda...ants may,access the live webcast via the Company,s...
...ct. 31 Allos,Therapeutics, Inc. (Nasdaq: ALTH ),...pment and commercialization of small molecule ther...ced that Paul L. Berns, President and,CEO, will pr... (Eastern) on,Tuesday, November 6, 2007. There wil...
... a record $175 million; net book-to-bill of 1.7:1,...an all-time Company high, - Third quarter operat... - Third quarter EPS of $0.25 (GAAP) and $0.48...endle (Nasdaq: KNDL ), a,leading, global full-ser...
...DVENTRX Pharmaceuticals,Inc. (Amex: ANX ), a biop...used on commercializing proprietary product candid...seases, announced today that Evan M. Levine,ADVENT...The conference takes place in New York at the Wald...
...t. 30 Medical Services,International Inc. (OTC Pi...as added 4 additional distributors in the month of...utorships these corporations will have to purchase...,a Dengue Fever Kit and only one other manufacture...
Other Medicine News:Health News:Biopure's Stock Symbol Reverts to BPUR 2Health News:Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference 2Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 2Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 3Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 4Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 5Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 6Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 7Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 8Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 9Health News:ADVENTRX Pharmaceuticals to Present at the 18th Annual CIBC Healthcare Conference 2
(Date:11/25/2009)..., MOUNTAINVIEW,Calif.,Nov.25/PRNewswire/-- Che...aldatafromtheCompany,sPROTECT-1(theProspectiveRand...fTraficet-EN(TM)(CCX282-B)inpatientswithmoderate-t...withafavorablesafetyandtolerabilityprofile.Thestud...ionofdiseaseseverityasdefinedasa70-pointdecreasein...
(Date:11/24/2009)..., PITTSBURGH,Nov.24/PRNewswire/-- ,, WHAT:Ro...arsfollowinganautoaccident,wasactuallyfullyconscio...ningAmericasegment.TheDynaVoxEyeMaxwasfeaturedinth...andotherconditionscanunlockcommunication. ,, WH...leonlineat www.dynavoxtech.com ,, WHO:Ro...
(Date:11/24/2009)..., MADISON,N.J.,Nov.24/PRNewswire-FirstCall/--Qu...eadingproviderofdiagnostictesting,informationandse...nnualPiperJaffrayHealthcareConferenceinNewYorkCity...2009at9:30a.m.EasternTime. ,, Duringtheconferen...growthtoapproximate3%,operatingincometoexceed18%of...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2LifeSpan Treadmill Awarded BEST TREADMILL by Health Magazine 52317 1LifeSpan Treadmill Awarded BEST TREADMILL by Health Magazine 52317 2Novavax Announces Appointment of John J Trizzino as Senior Vice President International and Government Alliances 13127 1Novavax Announces Appointment of John J Trizzino as Senior Vice President International and Government Alliances 13127 2Biomarkers May Predict Alzheimers 52316 1Biomarkers May Predict Alzheimers 52316 2Biomarkers May Predict Alzheimers 52316 3
...ns for treating returning vets and others exposed ... Schepens Eye Research Institute have shown for th...ause both eyes to lose a special protective abilit...ects the eye without the inflammation of the body,... delicate eye tissue. This finding, published in t...
...ExonHit Therapeutics,(Alternext: ALEHT) is pleased... lead compound in Alzheimer,s disease, is progress...l assessing EHT 0202 in patients with,Alzheimer,s ...tion of patient enrolment for the Phase IIa,repres...EHT 0202, and,provides a clear timeline for the re...
Other Medicine Technology:Laser Burn Injuries in One Eye Can Disrupt Protective Immune Privilege in Both Eyes, Study Finds 2ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease 2ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease 3ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease 4
Naked Gold 20 nm
Naked Gold 20 nm - 50 OD
CranioFix2 Titanium Clamp System
...ate, reliable, portable, and easy-to-use pachymete... a dual-rechargeable battery system that makes cha...lution, color, touch screen controls make operatin...ent software simplifies calculating adjustments to...
Medicine Products: